Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?   

This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeting. This question was inspired by the session "Novel Indications for Hypoglycemic Agents in Rheumatic Diseases: Sodium-Glucose Co-Transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists" by Dr. Louis Aronne, Dr. Brittany Weber and Dr. Isabelle Ayoub.